Does the Myval balloon-expandable THV reduce the rate of PPI and paravalvular leak compared to the ER self-expanding THV in patients with severe symptomatic AS undergoing TAVR?
In a registry of patients with severe symptomatic aortic stenosis, the Myval balloon-expandable valve showed comparable overall performance but lower rates of pacemaker implantation and paravalvular leak compared to the ER self-expanding valve.
In patients with severe symptomatic AS undergoing TAVR, the novel Myval BE THV provided a comparable performance to the well-known ER SE THV, and it was associated with a lower rate of PPI and ≥moderate PVL within 30 days and 6 months after the procedure. Randomized, head-to-head comparison trials are needed to confirm our results.
Barki et al. (Sat,) studied this question.